Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice

Multiple myeloma (MM) is the most common cancer affecting the bone and bone marrow and remains incurable for most patients; novel therapies are therefore needed. Bortezomib (Btz) is an FDA-approved drug for the treatment of patients with MM. However, its severe side effects require a dose reduction...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Hua Wang, Lifeng Xiao, Jianguo Tao, Venkat Srinivasan, Brendan F. Boyce, Frank H. Ebetino, Babatunde O. Oyajobi, Robert K. Boeckman, Lianping Xing
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2018-09-01
Serija:	Pharmaceutics
Teme:	drug delivery bortezomib velcade bone targeting multiple myeloma
Online dostop:	http://www.mdpi.com/1999-4923/10/3/154
Oznake:	Označite Brez oznak, prvi označite!